Cullinan Therapeutics (CGEM) investor relations material

Portfolio overview and strategic priorities

• 2026 marks the first year with catalysts across the entire portfolio, with a focus on two high-priority T cell engager programs: CLN-978 for autoimmune diseases and CLN-049 for AML.

• CLN-978 is positioned as a best-in-class CD19 x CD3 bispecific T cell engager, targeting lupus, RA, and Sjögren's disease, with data readouts planned throughout 2026.

• CLN-049, a FLT3 x CD3 T cell engager, has shown promising monotherapy efficacy in AML and received FDA Fast Track designation, with pivotal dose selection and combination studies planned.

• The company holds over $430 million in cash as of end 2025, providing runway into 2029 to advance key programs without near-term capital needs.

• Acquisition of a BCMA T cell engager expands reach to additional autoimmune diseases, making the company the only one with both clinical-stage CD19 and BCMA agents.

Clinical development and upcoming catalysts

• CLN-978 studies in lupus and RA have completed enrollment in the first three dose cohorts, with Q2 data to include at least nine lupus and seven RA patients.

• Initial Q2 data will focus on dose response for B cell depletion, with Q3 repeat dosing data expected to demonstrate more robust efficacy.

• Safety thresholds for outpatient use include robust remissions with no higher than Grade 1 CRS in most cases, single-digit Grade 2 CRS, and no ICANS.

• Treatment-free remission is a key differentiator, offering patients extended periods without medication, which is highly valued by both patients and physicians.

• The BCMA T cell engager targets diseases driven by long-lived plasma cells, such as myasthenia gravis and certain hematological and thyroid conditions.

Oncology program highlights

• CLN-049 demonstrated deep and durable complete responses in AML, including in high-risk genetic subgroups like P53 mutations and complex karyotypes.

• Response rates at the highest dose compared favorably to recently approved AML drugs, with potential for broad all-comer patient populations.

• Regulatory pathway includes dose expansion and optimization in 2026, with a Phase II pivotal study targeted for 2027 and potential accelerated approval.

• Strong KOL and investigator interest globally, with the ASH abstract selected for official highlights, reflecting the program's standout status.

• Plans to initiate a Phase 1b/2 combination study with AZA in previously untreated AML patients before year-end.